AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02765672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness-to-Drive Screening Measure (FTDS)
Description: Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
Study NCT02765672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simulated Driving Evaluation
Description: This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
Study NCT02765672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Simulated Driving Evaluation
Description: This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
Study NCT02765672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving Safety Education
Description: This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
Study NCT02765672 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occupational Therapy Driving Intervention (OT-DI)
Description: This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
Study NCT02765672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: On-road driving test
Description: This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
Study NCT02765672 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Driving triggers evaluation
Description: The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
Study NCT03176784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 0.5mg and 1.0 mg pills used. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
Study NCT03176784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: 14 mg and 7 mg nicotine patches used. See arms for specific durations.
Study NCT03176784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Patch
Description: Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
Study NCT04611685 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Immediately after the operation, the patient is given (tramadol 100 mg) intramuscularly once, and then given (tramcontin 100 mg) orally twice a day during the first three postoperative days.
Study NCT01735747 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
Study NCT01735747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin
Description: nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
Study NCT01735747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
Study NCT01735747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
Study NCT01045772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rilonacept
Description: 160mg of rilonacept 1x/week
Study NCT04576637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurophysiological monitoring during intubation
Description: In the operating room patients will be connected to the anesthesia monitor and an IV line as standard clinical practice. Participants will receive oxygen and an IV infusion of 1-3 ng/ml remifentanil via TCI infusion pump to achieve mild sedation. Patients will then be connected to the neurophysiological electrodes to monitor for EEG, EMG, SSEP and MEP signals. After preparing the videolaryngoscope, anesthesia induction will be achieved with the use of IV ketamine 2mg/kg. Then the anesthesiologist will perform a clinical and ECG reading assessment to ensure that the patient is anesthetized and will be able to titrate more ketamine as needed to achieve hypnosis. A biteblock will be located to prevent teeth damage. A neurophysiological baseline recordings will then be performed by a neurophysiologist. The videolaryngoscope will then be inserted, during which a second neurophysiological testing will be performed to ensure the patients safety. Then mechanical ventilation will be initiated.
Study NCT03129581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Counseling
Description: Counseling to only eat during a restricted amount of time.
Study NCT02114645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 mg oral estradiol valerate
Description: estrofem is given twice a day
Study NCT03176784 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Pill
Description: Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations. (Active and placebo varenicline pills provided at no cost through an independent research agreement with Pfizer.)
Study NCT03492970 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Hourly dosing of the nychtemeral secretion of melatonin
Description: Hourly dosing of the nychtemeral secretion of melatonin links and with sleep disorders and behavior of adult patients with SMS
Study NCT01087021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabazitaxel (XRP6258)
Description: Pharmaceutical form:solution for infusion~Route of administration: intravenous
Study NCT03655275 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PRP prolotherapy
Description: PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.
Study NCT03655275 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Saline prolotherapy
Description: Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.
Study NCT03028896 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 90° rotational technique
Description: the LMA FlexibleTM was rotated counter-clockwise through 90°
Study NCT02154724 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: aDBS
Description: The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
Study NCT02154724 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: DBS
Description: The aDBS s applied for two hous in DBS modality.
Study NCT03950856 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V114
Description: 15-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F in each 0.5 mL dose.
Study NCT03950856 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prevnar 13™
Description: 13-valent pneumococcal conjugate vaccine with serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5. mL dose.
Study NCT01983111 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: Dosage and administration: This one patch should be attached every 7 days.
Study NCT01983111 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tramadol/acetaminophen
Description: Amount of drug ingredients~: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.~Dosage and administration:~Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets.
Study NCT00473174 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril
Description: Dosing on awakening versus bedtime
Study NCT00473174 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
Study NCT01783977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT1 vaccine
Description: NYVAC-HIV-PT1 at greater than or equal to 5x10\^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10\^8 PFU/ml; administered as 1 mL IM in participant's deltoid
Study NCT00498212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS-HBsAg-Single
Description: Intramuscular (IM) injection at Day 0, Week 4 and Week 24
Study NCT00498212 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 1018 ISS-HBsAg-Double
Description: Intramuscular (IM) injection at Day 0, Week 4 and Week 24
Study NCT01350076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional liberal fluid regimen
Description: Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
Study NCT01350076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: restricted fluid regimen
Description: Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).~Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index
Study NCT02635295 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile cooperation during the clinical practicum
Description: The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.~Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT.
Study NCT04417985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT, MRI
Study NCT03145220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EA-230
Description: Active intervention
Study NCT03145220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (NaCl)
Description: Placebo intervention
Study NCT01483560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 3 years treatment duration
Study NCT01483560 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 years duration
Study NCT01734902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Description: sugar coated tablets for oral administration
Study NCT01734902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyoscine butylbromide
Description: drops for oral administration
Study NCT02395276 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Whole body hypothermia
Description: Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
Study NCT01783977 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NYVAC-HIV-PT4 vaccine
Description: NYVAC-HIV-PT4 at greater than or equal to 5x10\^6 PFU/ml for a planned maximum dose of 1.1x10\^7 PFU/ml; administered as 1 mL IM in participant's deltoid
Study NCT02395276 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Whole body hypothermia
Description: Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
Study NCT02578901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
Study NCT02578901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
Study NCT04426474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3502970
Description: Administered orally.
Study NCT04426474 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT02027792 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cabbage leave wraps
Study NCT02027792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac Gel
Study NCT00397540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PEIT
Description: Percutaneous Ethanol Injection Therapy
Study NCT00397540 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFTA
Description: Radiofrequency Thermal Ablation
Study NCT03290027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFD-03
Description: DFD-03 Lotion
Study NCT03290027 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Vehicle (tazarotene 0%) Lotion
Study NCT01783977 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for DNA-HIV-PT123 vaccine
Description: Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
Study NCT01783977 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT1 vaccine
Description: Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
Study NCT01783977 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for NYVAC-HIV-PT4 vaccine
Description: Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
Study NCT01482013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HPP854
Description: Oral, once a day for 28 days.
Study NCT01482013 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral, once a day for 28 days.
Study NCT01640821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CdM? program
Description: The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
Study NCT05633368 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Participants will be contacted every three weeks to assess depressive symptomatology and possible relapse.~* Patient Health Questionnaire (PHQ-9)~* Clinical Global Impression (CGI)~* Scaling question regarding depressive symptomatology
Study NCT01444235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custodiol-N
Description: Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
Study NCT01444235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Custodiol
Description: Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
Study NCT01777893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High protein/ high intensity physical activity (HP-HI)
Description: Participants follow a high protein diet and a high intensity physical activity intervention
Study NCT01777893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High protein / moderate intensity physical activity (HP-MI)
Description: Participants follow a high protein diet and moderate intensity physical activity intervention
Study NCT01777893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate protein/ high intensity physical activity (MP-HI)
Description: Participants follow a moderate protein diet and a high intensity physical activity intervention
Study NCT01777893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate protein/ moderate intensity physical activity (MP-MI)
Description: Participants follow a moderate protein diet and moderate intensity physical activity intervention
Study NCT02993510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
Study NCT02993510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondro-Gide sutured
Description: Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
Study NCT02993510 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondro-Gide glued
Description: Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
Study NCT01425983 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: amino acid composition (asn01)
Description: Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Duration: 12 weeks
Study NCT01425983 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.~Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.~Duration: 12 weeks
Study NCT02305901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: single dose on day 1 of visits 2 and 3
Study NCT02305901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004 tablet
Description: multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
Study NCT02305901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bupropion extended release tablet
Description: single dose on day 3 of visits 2 and 3
Study NCT00458406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bi-Flex
Description: Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.~Positive pressure used during sleep for 3 months
Study NCT00458406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.~Positive pressure used during sleep for 3 months.
Study NCT02837692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 10 milligram (mg)
Description: JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
Study NCT02837692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 20 mg
Description: JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
Study NCT02837692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-42847922 40 mg
Description: JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.